These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 11754641

  • 1. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S, Laird D, Cherrington JM, Knox SJ.
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
    Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW.
    Cancer Res; 2002 Mar 15; 62(6):1702-6. PubMed ID: 11912143
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.
    Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140
    [Abstract] [Full Text] [Related]

  • 7. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
    Heryanto B, Lipson KE, Rogers PA.
    Reproduction; 2003 Mar 15; 125(3):337-46. PubMed ID: 12611597
    [Abstract] [Full Text] [Related]

  • 8. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
    Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM.
    Cancer Res; 2001 Feb 15; 61(4):1464-8. PubMed ID: 11245452
    [Abstract] [Full Text] [Related]

  • 9. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
    Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B.
    Cancer Chemother Pharmacol; 2005 Dec 15; 56(6):569-77. PubMed ID: 16001166
    [Abstract] [Full Text] [Related]

  • 10. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
    Ellis LM, Takahashi Y, Liu W, Shaheen RM.
    Oncologist; 2000 Dec 15; 5 Suppl 1():11-5. PubMed ID: 10804085
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
    Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM.
    FASEB J; 2002 May 15; 16(7):681-90. PubMed ID: 11978732
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
    Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM.
    Blood; 2001 Mar 01; 97(5):1413-21. PubMed ID: 11222388
    [Abstract] [Full Text] [Related]

  • 17. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
    Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.
    Mol Cancer Ther; 2006 May 01; 5(5):1280-9. PubMed ID: 16731761
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM.
    Medicina (B Aires); 2000 May 01; 60 Suppl 2():41-7. PubMed ID: 11188930
    [Abstract] [Full Text] [Related]

  • 19. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P, Thurnher A, Hirth KP, Schilling L, Schmiedek P, Ullrich A, Menger MD.
    Oncologist; 2000 May 01; 5 Suppl 1():16-9. PubMed ID: 10804086
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
    Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):678-89. PubMed ID: 15701856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.